Evidence map›Paper›PMID 35419616›Full record

ReviewInternational journal of molecular medicine2022

Focus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (Review).

Xiaolu Zhang, Wenyun Zeng, Yue Zhang, Qun Yu, Miao Zeng, Jiali Gan, Wenlan Zhang, Xijuan Jiang, Huhu Li

Open access · hybridAbstract readReview
In one paragraph

Review in International journal of molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaolu ZhangSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Wenyun ZengSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Yue ZhangSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Qun YuSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Miao ZengSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Jiali GanSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Wenlan ZhangSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Xijuan JiangSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Huhu LiSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Tianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post‑ischemic neuroinflammation induced by the innate local immune response is a major pathophysiological feature of cerebral ischemic stroke, which remains the leading cause of mortality and disability worldwide. NLR family pyrin domain containing (NLRP)3 inflammasome crucially mediates post‑ischemic inflammatory responses via its priming, activation and interleukin‑1β release during hypoxic‑ischemic brain damage. Mitochondrial dysfunctions are among the main hallmarks of several brain diseases, including ischemic stroke. In the present review, focus was addressed on the role of mitochondria in cerebral ischemic stroke while keeping NLRP3 inflammasome as a link. Under ischemia and hypoxia, mitochondria are capable of controlling NLRP3 inflammasome‑mediated neuroinflammation through mitochondrial released contents, mitochondrial localization and mitochondrial related proteins. Thus, inflammasome and mitochondria may be attractive targets to treat ischemic stroke as well as the several drugs that target the process of mitochondrial function to treat cerebral ischemic stroke. At present, certain drugs have already been studied in clinical trials.

Indexed as

Ischemic StrokeStrokeHumansInflammasomesMitochondriaNLR Family, Pyrin Domain-Containing 3 ProteinProspective StudiesInflammasomesNLR Family, Pyrin Domain-Containing 3 Proteinischemic strokemitochondrianeuroinflammationNLR family pyrin domain containing 3 inflammasometreatment

Identifiers

PMID35419616
PMCPMC9015651
OpenAlexW4224013823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.